Immunotherapy with checkpoint inhibitors (CPI), i.e. anti-PD-1, anti PD-L1 and CTLA-4 antibodies has dramatically improved survival rates in various cancer types during the last decade and they are frequently used in different treatment settings (1–3). This evidence concerns the gene CD274 and cancer.